Is Androst-4-en-3-one, 17-beta-hydroxy- Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Androst-4-en-3-one, 17-beta-hydroxy-? Is Androst-4-en-3-one, 17-beta-hydroxy- safe for nursing mother and child? Does Androst-4-en-3-one, 17-beta-hydroxy- extracts into breast milk? Does Androst-4-en-3-one, 17-beta-hydroxy- has any long term or short term side effects on infants? Can Androst-4-en-3-one, 17-beta-hydroxy- influence milk supply or can Androst-4-en-3-one, 17-beta-hydroxy- decrease milk supply in lactating mothers?
Androst-4-en-3-one, 17-beta-hydroxy- lactation summary
- DrLact safety Score for Androst-4-en-3-one, 17-beta-hydroxy- is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of Androst-4-en-3-one, 17-beta-hydroxy- may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that Androst-4-en-3-one, 17-beta-hydroxy- may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of Androst-4-en-3-one, 17-beta-hydroxy- low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using Androst-4-en-3-one, 17-beta-hydroxy- We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Androst-4-en-3-one, 17-beta-hydroxy- usage in lactation
Androst-4-en-3-one, 17-beta-hydroxy- hormone reduces Prolactin serum levels and may likely inhibit milk production mainly soon after delivery. No significant increase of Androst-4-en-3-one, 17-beta-hydroxy- serum levels neither in the mother´s milk nor in the infant’s serum have been found after administration to the mother. No adverse side effects have been noticed in the infant.
Answer by DrLact: About Androst-4-en-3-one, 17-beta-hydroxy- usage in lactation
Limited data indicate that a low-dose (100 mg) subcutaneous Androst-4-en-3-one, 17-beta-hydroxy- pellet given to a nursing mother appears not to increase milk Androst-4-en-3-one, 17-beta-hydroxy- levels markedly. Androst-4-en-3-one, 17-beta-hydroxy- has low oral bioavailability because of extensive first-pass metabolism, so it is unlikely to affect the breastfed infant. One breastfed infant seemed not to be adversely affected by low-dose maternal Androst-4-en-3-one, 17-beta-hydroxy- therapy.
Androst-4-en-3-one, 17-beta-hydroxy- Side Effects in Breastfeeding
An infant (age not stated) was breastfed (extent not stated) after implantation of 100 mg of Androst-4-en-3-one, 17-beta-hydroxy- subcutaneously. No adverse effects were noted in the infant over a 5-month period.[1]
Androst-4-en-3-one, 17-beta-hydroxy- Possible Effects in Breastfeeding
Supraphysiologic serum levels of Androst-4-en-3-one, 17-beta-hydroxy-, either from a tumor[2][3] or from exogenously administered Androst-4-en-3-one, 17-beta-hydroxy-,[4] reduces milk production in postpartum women. Androst-4-en-3-one, 17-beta-hydroxy- alone reduces serum prolactin;[4] however, when given in combination with estrogen and progestin, serum prolactin levels are not markedly reduced.[5] Androst-4-en-3-one, 17-beta-hydroxy- was previously used therapeutically to suppress lactation, usually in combination with an estrogen.[4][5][6][7][8][9][10]
Alternate Drugs
Testosterone(Low Risk)
Estradiol Valerate(Low Risk)
Testosterone(Low Risk)
Progesterone(Safe)
Estradiol(Low Risk)